Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women

April 30, 2018

OBE022

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women…

Read more

ObsEva on page 17 of Understanding Fertility Special Report 2018

April 24, 2018

Nolasiban

Special report in the Raconteur Article in ‘The Times’ Click here for publication link IVF ‘BREAKTHROUGH’ TREATMENT Pioneering use of…

Read more

Effects of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022 on Reproduction in Rats and Rabbits

March 10, 2018

OBE022

Oliver Pohl, Roberta Sisti, Jean-Pierre Gotteland SRI Conference, 06-10 March 2018, San Diego, CA

Read more

Safety and Pharmacokinetics of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022: A First-in-Human Study in Healthy Women

OBE022

Oliver Pohl, Ulrike Lorch, Line Marchand, Jean-Pierre Gotteland SRI Conference, 06-10 March 2018, San Diego, CA

Read more

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments

February 28, 2018

OBE022

Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl Confirmation of the Cardiac…

Read more

GnRH Receptor Antagonist Mono- And Combination Therapy With E2/NETA Add-Back – Pharmacodynamics And Safety Of OBE2109

December 4, 2017

Linzagolix

GnRH Receptor Antagonist Mono- And Combination Therapy With E2/NETA Add-Back – Pharmacodynamics And Safety Of OBE2109S Pohl O, Marchand L,…

Read more

Confirmation of the Cardiac Safety of OBE022 in a First in Human Study in Healthy Subjects using Intensive ECG Assessments and the Effect of a Meal on QTc to Show Assay Sensitivity

September 19, 2017

OBE022

J. Täubel, U. Lorch , G. Ferber , O Pohl ACCP Conference, 17-19 September 2017, San Diego, CA

Read more

A placebo-controlled, randomized, double-blind study of pregnancy and live birth rates after single oral administration of a novel oxytocin antagonist, nolasiban, prior to embryo transfer

July 5, 2017

Nolasiban

H. Tournaye, A. Humberstone, V. Lecomte, P. Terrill, P. Pierzynski, E. Loumaye ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva,…

Read more

Combination tocolytics on the inhibition of OT-induced contractions of human pregnant myometrium in vitro

Nolasiban

L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou ESHRE 33rd Annual Meeting,…

Read more

FP receptor antagonist, OBE002, inhibits both PGF2α- and OT-induced contractions of human pregnant myometrium in vitro

Nolasiban

L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou ESHRE 33rd Annual Meeting,…

Read more